secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmonx Corp (LUNG)
CIK:        0001127537
Form:       8-K
Filed at:   2024-10-30T23:59:59+00:00
Accession:  0001127537-24-000082
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmonx Q3 2024 revenue $20.4M (+15% YoY), net loss $14.1M
----------------------------------------------------------

- Worldwide revenue $20.4M, up 15% YoY; U.S. revenue $13.8M (+17% YoY); international $6.6M (+12%).
- Gross margin 74% unchanged YoY; net loss $14.1M ($0.36 loss per share) vs $14.9M ($0.39) in Q3 2023.
- Adjusted EBITDA loss $8.1M vs $9.0M in Q3 2023; cash & marketable securities $107.8M as of Sep 30.
- Full-year 2024 revenue guidance reaffirmed $81M-$84M; op ex guidance narrowed to $122M-$124M.
- Added 15 new Zephyr Valve U.S. treatment centers; AeriSeal CONVERT trial showed 77.6% conversion rate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1127537/000112753724000082/0001127537-24-000082-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1127537/000112753724000082/lung-20241030.htm
  HTML page:      https://secwatch.observer/filing/0001127537-24-000082

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer